Richmond Pharmacology

We're more than a slogan, our work speaks for itself.

Fast. Efficient. Personable.

Founded in 2001, Richmond Pharmacology is currently one of fifteen MHRA accredited phase one units in the UK.

Try Our Method.

As renowned pioneers in practical Adaptive Study Design, we actively work to maximise return on our sponsors’ clinical trials.

Getting involved in clinical research

Patients and network staff talk about their experiences of being involved in clinical research.

Novel drugs, Implantable Devices & Atrial Fibrillation Burden - Prof John Camm.

Join Professor John Camm for his discussion on Atrial Fibrillation.

BBC Breakfast News

Patients and network staff talk about their experiences of being involved in clinical research.

Atrial Fibrillation Antiarrhythmic Drugs.

Professor John Camm discusses the two newest antiarrhythmic drugs dronedarone (Multaq®), which is now approved in the US and Europe for atrial fibrillation, and vernakalant, which is a year or two away.

Watch us work.

Now's your chance to watch us work - check out the video below for a snapshot of our bustling team in action.